Vimarsana
Biggest News Aggregation in the World

Af302 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Af302. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Af302 Today - Breaking & Trending Today

Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA - Vimarsana News

Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA

Published: July 7, 2022

Positive biomarker data confirmed in additional subjects and at additional timepoints Stable or continuously increasing cognitive, language and motor functions observed in patients treated

Source: finanznachrichten.de
Related Topics:
United StatesRaymond WangFoundation Of Caring Multidisciplinary Lysosomal Disorder ProgramSanfilippo Community ConferenceWeizmann Institute Of ScienceBayley Scales Of Infant DevelopmentCommunity ConferenceAnnual Gene TherapyNeurological Disorders EuropeInfant DevelopmentMarie TradMedical OfficerWeizmann InstituteFrench AutoritDes MarchFrench Markets AuthoritiesDurant Des AulnoisFinancial Officer
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights - Vimarsana News

Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights

Published: January 13, 2022

Lysogene remains focused on developing its pipeline led by LYS-SAF302, LYS-GM101, Fragile X and other high potential preclinical projects Regulatory News: Lysogene (FR0013233475 LYS) (Paris:LYS)

Source: finanznachrichten.de
Related Topics:
France GeneralKaren AiachaddedGaucher ParkinsonKaren AiachEuropean UnionOrphan Drug DesignationFast TrackRare Pediatric DiseaseChief Executive OfficerFrench AutoritDes MarchFrench Markets AuthoritiesDurant Des AulnoisFinancial Officer